- Home
- MKTW vs OTLK Comparison
MKTW vs OTLK Comparison
Compare MKTW & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | OTLK |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 42.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MKTW | OTLK |
|---|---|---|
| Price | $16.16 | $1.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $20.00 | $5.25 |
| AVG Volume (30 Days) | 9.4K | ★ 5.0M |
| Earning Date | 11-06-2025 | 12-26-2025 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $342,206,000.00 | $1,505,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $342.80 |
| P/E Ratio | $6.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.08 | $0.79 |
| 52 Week High | $21.74 | $3.39 |
Technical Indicators
Market Signals| Indicator | MKTW | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 61.42 |
| Support Level | $15.85 | $1.51 |
| Resistance Level | $16.50 | $2.02 |
| Average True Range (ATR) | 0.46 | 0.21 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 19.66 | 65.34 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.